A total of 5 randomized, double-blind trials in patients with hypercholesterolemia were
prospectively designed to allow pooling of plasma lipid data after 12 weeks of treatment. The …

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are
effective in reducing the risk of coronary events, and are generally very well tolerated …

Statins are an established class of drugs with proven efficacy in cardiovascular risk
reduction. The concern over statin safety was first raised with the revelation of myopathy and …

The major therapeutic action of statin drugs is reduction in levels of circulating atherogenic
lipoproteins as a result of inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) …

Objective: To examine the efficacy and tolerability of rosuvastatin 5 mg at daily and non-daily
dosing regimens. Research design and methods: A retrospective survey was conducted at …

Background: As the clinical complexity of patients at high cardiovascular risk and with
multiple comorbid conditions increases, so does the potential for drug–drug interactions …

Background Rosuvastatin is one of the most potent statins and is currently widely
prescribed. It is therefore important to know the dose-related magnitude of effect of …

Patients at risk of coronary heart disease may not achieve recommended low-density
lipoprotein (LDL) cholesterol goals on statin monotherapy. This study was designed to …

We report here a case of clinically significant liver toxicity after a brief course of rosuvastatin,
which is the first statin approved by the regulatory authorities since the withdrawal of …

OBJECTIVE: The aim of this study is to compare the non-lipid effects of rosuvastatin–
fenofibrate combination therapy with rosuvastatin monotherapy in high-risk Asian patients …